Forma Therapeutics, Inc.

Novo Nordisk Healthcare Ag

Cara Therapeutics, Inc.

Forma Tm2, Inc.

Gary Gustafson

David R Lancia, Jr

Zhongguo Wang

Anna M Ericsson

Jian Lin

Justin Andrew Caravella

Ann-Marie Campbell

Susan Ashwell

Wei Lu

R Bruce Diebold

Neal Green

Tatiana Shelekhin

Lorna Mitchell

David James Richard

Xiaozhang Zheng

Bingsong Han

Chase C Smith

Alexandre Joseph Buckmelter

Stephanos Ioannidis

Minghua Wang

Bruce Follows

Gary Marshall

Janet L Ralbovsky

Edward L Fritzen

R Paul Beckett

Carla M Gauss

Jason S Newcom

Richard Foster

Christelle Henault

Stephen J O'Connor

Robert Zhiyong Luo

Zhiyong Luo

David R Lancia

Patrick F Kelly

Madhu Mondal

Sanjeev Forsyth

Maria Ribadeneira

Patricia Schroeder

Mary-Margaret E Zablocki

David Lancia

Jr David R Lancia

David R Lancia Jr

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W, W, W, R-R, and Rare described herein.

Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

Activating pyruvate kinase R

The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators

Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Treating sickle cell disease with a pyruvate kinase R activating compound

The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R, R, R, R, R, R, X, X, X, X, and n are described herein.

Purinones as ubiquitin-specific protease 1 inhibitors

This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.

Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).

Compositions for activating pyruvate kinase

The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia. 

The disclosure provides chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

Activating pyruvate kinase R and mutants thereof

Growing community of inventors

Ridgefield, CT, United States of America

Gary Gustafson